While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

CSL Behring KK has gained approval from Japan's MHLW to manufacture and market subcutaneous injection 200mg Andembry pens.

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...